Tag: Gleevec

Novartis Ruling Reverberates Past India’s Borders

India’s Supreme Court says drug maker Novartis can’t hold onto its patent for the pricey cancer drug Gleevec simply by tweaking its chemical formula. That means generic drug makers can keep making a form of the drug at a tenth of Novartis’s price. Consumer advocates call it a major advance...

Read More

Novartis Hearing Update: Supreme Court commences final hearing

11 September 2012, New Delhi. The final hearing of the petition filed by Novartis AG, challenging the order of the Intellectual Property Appellate Board (IPAB) rejecting its appeal relating to its patent application for the beta-crystalline form of imatinib mesylate, and related petitions commenced today before a bench of the...

Read More

Current Cases

Novartis AG v. Union of India and Others, SLP (Civil) Nos. 20539–20549 of 2009 In this case, which is presently before the Supreme Court of India, Novartis AG (Novartis) challenges the order of the Intellectual Property Appellate Board (IPAB) rejecting its patent application for Gleevec (beta crystalline form of imatinib...

Read More